Healthcare
Live Price
Offline$54.65
+0.00% today
Window Change
+1.15%
Window
Jun 23, 2025 → Dec 9, 2025
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 119 bars · Jun 23, 2025 → Dec 9, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Akero Therapeutics, Inc. (AKRO) is a Healthcare stock with a market cap of $4.50B. The stock last traded around $54.65 and up 1.1% across the available one-year price window (Jun 23, 2025 → Dec 9, 2025). Baseline metrics include revenue growth of 0.0%, EPS growth of -29.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -29.8%, free cash flow -59.0% with operating margin 0.0% and ROIC -34.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AKRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AKRO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AKRO Max Drawdown
-25.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AKRO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$79.2M
+21.4% YoY
Free Cash Flow
-$71.0M
+11.0% YoY
Revenue Growth
+0.0%
EPS Growth
-29.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -213K |
| Operating Income | -285M | -173M | -115M | -101M | -80M |
| EBITDA | -247M | -149M | -111M | -101M | -79M |
| Net Income | -252M | -152M | -112M | -101M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 340M | 234M | 250M | 150M | 187M |
| Total Assets | 826M | 580M | 357M | 196M | 273M |
| Total Liabilities | 76M | 45M | 30M | 26M | 15M |
| Shareholder Equity | 750M | 535M | 327M | 169M | 259M |
| Total Debt | 36M | 26M | 11M | 2M | 2M |
| Net Debt | -304M | -208M | -239M | -149M | -185M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
+11.1% YoY
Capital Expenditures
148K
Free Cash Flow
71M
+11.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-30.7%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.